Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

International, Randomized, Multicenter, Phase IIIb Study in Patients With Relapsing-Remitting Multiple Sclerosis Comparing Over a Treatment Period of 104 Weeks: 1. Double-Blinded Safety, Tolerability, and Efficacy of Betaseron/ Betaferon 250 microg (8 MIU) and Betaseron/-Betaferon 500 microg (16 MIU), Both Given Subcutaneously Every Other Day, and 2. Rater-Blinded Safety, Tolerability, and Efficacy of Betaseron/-Betaferon s.c. Every Other Day With Copaxone 20 mg s.c. Once Daily.

Next Previous
X
Search
Trial Profile

International, Randomized, Multicenter, Phase IIIb Study in Patients With Relapsing-Remitting Multiple Sclerosis Comparing Over a Treatment Period of 104 Weeks: 1. Double-Blinded Safety, Tolerability, and Efficacy of Betaseron/ Betaferon 250 microg (8 MIU) and Betaseron/-Betaferon 500 microg (16 MIU), Both Given Subcutaneously Every Other Day, and 2. Rater-Blinded Safety, Tolerability, and Efficacy of Betaseron/-Betaferon s.c. Every Other Day With Copaxone 20 mg s.c. Once Daily.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 May 2017

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon beta-1b (Primary) ; Glatiramer acetate
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms BEYOND
  • Sponsors Bayer HealthCare Pharmaceuticals Inc.

    • Most Recent Events

    • 12 Oct 2015 Results published in the JAMA Neurology
    • 01 Feb 2012 Results reporting neutralising antibody titres published in the Multiple Sclerosis Journal.
    • 10 Sep 2009 Results investigating the effects of treatment on the incidence of depression have been presented at 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top